COX-1 and COX-2 contribute differentially to the LPS-induced release of PGE2 and TxA2 in liver macrophages.

LPS induces an immediate release of thromboxane TxA2 and a delayed release of PGE2. Dexamethasone suppresses the LPS-induced release of TxA2 and PGE2. In the first 8 h after LPS addition, the specific COX-2 inhibitor SC236 inhibits the PGE2 and TxA2 release by about 80% and 20%, whereas the release of PGE2 and TxA2 between 8 and 24 h is inhibited by about 40% and 35%, respectively.

PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages.

Lipopolysaccharide (LPS) induces a release of tumor necrosis factor (TNF)-alpha, endothelin (ET)-1, interleukin (IL)-1alpha, IL-6 and IL-10 in rat liver macrophages (Kupffer cells). Prostaglandin (PG)E2 inhibits the release of the fibrogenic mediators TNF-alpha, ET-1 and IL-1alpha, and enhances the release of the anti-fibrogenic mediators IL-6 and IL-10. This effect of PGE2 is mimicked by specific agonists for the PGE2 receptors EP2 and EP4; whereas, agonists for the PGE2 receptors EP1 and EP3 are inactive.

Diverse functional coupling of cyclooxygenase 1 and 2 with final prostanoid synthases in liver macrophages.

Lipopolysaccharide (LPS) treatment of resident liver macrophages resulted in a coordinated enhanced expression of cytosolic phospholipase A(2) (cPLA(2)), cyclooxygenase (COX)-2 and prostaglandin E(2)-synthase. LPS-pretreated liver macrophages showed a higher release of PGE(2) after zymosan, phorbol ester and A23187, of PGF(2alpha) after zymosan and A23187, whereas the release of thromboxane B(2) and PGD(2) was unchanged. Inhibition of COX-1 and -2 by specific inhibitors (SC560, SC236) inhibited the prostanoid release between 50-80% and 20-40%, respectively, indicating a predominant role for COX-1.